Verona Pharma PLC American Depositary Share (VRNA) Competitors $104.90 +0.12 (+0.11%) Closing price 04:00 PM EasternExtended Trading$104.86 -0.05 (-0.04%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRNA vs. ARGX, ONC, BNTX, INSM, SMMT, TEVA, ITCI, GMAB, MRNA, and RDYShould you be buying Verona Pharma PLC American Depositary Share stock or one of its competitors? The main competitors of Verona Pharma PLC American Depositary Share include argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Verona Pharma PLC American Depositary Share vs. Its Competitors argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories argenex (NASDAQ:ARGX) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do insiders & institutionals have more ownership in ARGX or VRNA? 60.3% of argenex shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ARGX or VRNA more profitable? argenex has a net margin of 40.20% compared to Verona Pharma PLC American Depositary Share's net margin of 0.00%. argenex's return on equity of 16.15% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets argenex40.20% 16.15% 14.33% Verona Pharma PLC American Depositary Share N/A -69.65%-28.00% Which has higher valuation & earnings, ARGX or VRNA? argenex has higher revenue and earnings than Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenex$2.25B15.34$833.04M$16.2134.83Verona Pharma PLC American Depositary Share$42.28M211.21-$173.42M-$2.00-52.45 Does the media refer more to ARGX or VRNA? In the previous week, Verona Pharma PLC American Depositary Share had 10 more articles in the media than argenex. MarketBeat recorded 25 mentions for Verona Pharma PLC American Depositary Share and 15 mentions for argenex. argenex's average media sentiment score of 1.16 beat Verona Pharma PLC American Depositary Share's score of 0.44 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 12 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ARGX or VRNA? argenex has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Do analysts rate ARGX or VRNA? argenex presently has a consensus price target of $728.06, suggesting a potential upside of 28.95%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, suggesting a potential upside of 3.91%. Given argenex's stronger consensus rating and higher possible upside, equities analysts plainly believe argenex is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 2 Strong Buy rating(s) 3.10Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15 Summaryargenex beats Verona Pharma PLC American Depositary Share on 13 of the 17 factors compared between the two stocks. Get Verona Pharma PLC American Depositary Share News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRNA vs. The Competition Export to ExcelMetricVerona Pharma PLC American Depositary ShareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.92B$2.96B$5.54B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-52.4519.7528.0119.82Price / Sales211.21299.50432.7298.44Price / CashN/A42.5936.1658.27Price / Book40.987.678.125.65Net Income-$173.42M-$55.28M$3.25B$257.91M7 Day Performance0.07%2.50%0.97%2.09%1 Month Performance15.38%11.70%7.36%11.13%1 Year Performance364.57%4.89%31.31%18.40% Verona Pharma PLC American Depositary Share Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRNAVerona Pharma PLC American Depositary Share2.2988 of 5 stars$104.90+0.1%$109.00+3.9%+358.8%$8.92B$42.28M-52.4530ARGXargenex4.4954 of 5 stars$561.28+0.2%$728.06+29.7%+23.6%$34.35B$2.25B34.631,599Positive NewsAnalyst RevisionONCBeOne Medicines2.5583 of 5 stars$252.14+0.7%$320.67+27.2%N/A$27.63B$3.81B-67.7811,000Analyst ForecastGap UpBNTXBioNTech1.4591 of 5 stars$111.00-1.7%$137.91+24.2%+28.4%$26.68B$2.98B-32.656,772Analyst ForecastINSMInsmed3.8659 of 5 stars$101.89+3.8%$108.07+6.1%+37.9%$19.33B$381.03M-17.121,271Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics2.886 of 5 stars$25.40+1.6%$34.67+36.5%+196.8%$18.86BN/A-74.70110TEVATeva Pharmaceutical Industries4.1195 of 5 stars$16.43+0.2%$24.71+50.5%-0.4%$18.84B$16.54B-14.2836,830ITCIIntra-Cellular Therapies0.9187 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9168 of 5 stars$21.46+0.3%$37.80+76.1%-18.0%$13.77B$3.12B12.192,682Positive NewsAnalyst RevisionMRNAModerna4.2835 of 5 stars$32.88-2.3%$46.61+41.8%-74.0%$12.72B$3.24B-3.775,800Trending NewsOptions VolumeAnalyst RevisionRDYDr. Reddy's Laboratories2.3577 of 5 stars$14.58+0.4%$16.95+16.3%-6.6%$12.17B$325.54B22.0827,811News CoverageUpcoming Earnings Related Companies and Tools Related Companies ARGX Alternatives ONC Alternatives BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRNA) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma PLC American Depositary Share Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma PLC American Depositary Share With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
